Empire Life Investments’s Arcturus Therapeutics ARCT Stock Holding History

Empire Life Investments’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.46M	Sell	366,217 -17,276	-5%	-$136K	0.14%	87
2026 Q1	$3.01M	Sell	383,493 -28,909	-7%	-$211K	0.18%	80
2025 Q4	$2.53M	Sell	412,402 -5,161	-1%	-$55.7K	0.14%	85
2025 Q3	$7.7M	Buy	417,563 +153,551	+58%	+$2.47M	0.45%	60
2025 Q2	$3.43M	Sell	264,012 -897	-0.3%	-$10.6K	0.22%	78
2025 Q1	$2.81M	Sell	264,909 -14,554	-5%	-$231K	0.18%	83
2024 Q4	$4.74M	Buy	279,463 +128,771	+85%	+$2.42M	0.3%	67
2024 Q3	$3.5M	Buy	+150,692	New	+$3.22M	0.21%	72

Other funds holding ARCT

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

DWM

Diversify Wealth Management Sandy, Utah $5.98B AUM 29.21% 1-Year Est. Return

Empire Life Investments's ARCT Position: Q2 2026 in Review

Empire Life Investments reduced its Arcturus Therapeutics (ARCT) stake by 4.5% in Q2 2026, selling an estimated $136K and leaving 366,217 shares worth $2.46M. The position accounts for 0.14% of the portfolio, ranked #87.

Empire Life Investments first reported a position in ARCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.7M in Q3 2025. 27 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Empire Life Investments held 366,217 shares of Arcturus Therapeutics worth $2.46M as of Q2 2026.
Empire Life Investments sold 17,276 Arcturus Therapeutics shares in Q2 2026, an estimated $136K.
Arcturus Therapeutics made up 0.14% of Empire Life Investments's portfolio in Q2 2026, its #87 holding.
Empire Life Investments first reported a position in Arcturus Therapeutics in Q3 2024 and has held it in 8 quarters since.
Empire Life Investments's Arcturus Therapeutics position peaked at $7.7M in Q3 2025.
27 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Empire Life Investments's 13F filing for Q2 2026, filed 24 Jul 2026.